Group 1 - Boston Scientific announced the acquisition of Penumbra for approximately $14.5 billion [1]

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction i MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement ...

Company Overview - The company, Penumbra, was founded in 2004 and is headquartered in Alameda, California, with over 4,500 employees worldwide [2] - Penumbra's products are available in over 100 markets globally [2] Manufacturing Insights - The company operates 9 buildings in Alameda, with 260,000 square feet dedicated to manufacturing [3] - Penumbra is recognized for its innovative approach and frequent product iterations [3]

Summary of Penumbra FY Conference Call (January 12, 2026) Company Overview - **Company**: Penumbra (NYSE:PEN) - **Founded**: 2004 - **Headquarters**: Alameda, California - **Employees**: Over 4,500 worldwide - **Manufacturing**: All products currently manufactured in California, with plans for expansion in Costa Rica by mid to late 2027 [2][4] Manufacturing and Expansion - **Current Facilities**: Nine buildings in Alameda, with 260,000 sq ft dedicated to manufacturing [3] - **New Facilities**: - Roseville facility: 300,000 sq ft, successful expansion [4] - Costa Rica facility: 330,000 sq ft, expected to open in mid to late 2027 [4] Business Segments - **Thrombectomy**: Focused on growth, with significant market share in mechanical thrombectomy [5][7] - **Embolization**: Both peripheral and neuro embolization segments are growing significantly [5] Market Insights - **Thrombectomy Market**: - Estimated 250,000 patients in the U.S. for arterial thrombectomy [6] - DVT (Deep Vein Thrombosis) represents the largest opportunity with a focus on iliofemoral DVTs [8] - Stroke market has about 200,000 patients, with over 30% penetration [10] - **Emerging Technologies**: Introduction of CAVT (computer-assisted vacuum thrombectomy) is expected to enhance treatment outcomes [11] Clinical Trials and Product Development - **STORM-PE Trial**: - Landmark trial for pulmonary embolism, showing significant safety and efficacy [12][13] - Procedure time was notably low at 25 minutes, with significant improvements in patient outcomes [13][14] - **Regulatory Updates**: Ongoing communication with the FDA regarding product submissions, with no major concerns reported [25] Growth Drivers and Challenges - **Growth Drivers**: - Anticipated recovery in the Chinese market, which had been a headwind [29] - Increased focus on embolization and thrombectomy as separate business units [29] - **Challenges**: - Need to convert physicians from traditional methods to newer technologies [41] - Structural issues in stroke care delivery remain a challenge [62] Financial Performance and Projections - **Margins**: Commitment to achieving 70%+ gross margins, with expectations for continued improvement [64] - **Growth Outlook**: Anticipated mid-teens growth with over 30% growth on the bottom line [26] Conclusion - **Innovation Commitment**: Penumbra emphasizes ongoing innovation and product development to enhance treatment options and patient outcomes [22] - **Market Position**: The company is positioned as a leader in mechanical thrombectomy, with a strong focus on expanding its market share in both thrombectomy and embolization [41][43]

Copyright ©2026 Penumbra, Inc. All rights reserved. Copyright ©2026 Penumbra, Inc. All rights reserved. 2 Copyright ©2026 Penumbra, Inc. All rights reserved. 3 Copyright ©2026 Penumbra, Inc. All rights reserved. 4 Copyright ©2026 Penumbra, Inc. All rights reserved. 5 | Arterial | Venous / DVT | PE | Coronary | Stroke | | --- | --- | --- | --- | --- | | Patients2 | Patients® | Patients' | Patients® | Patients® | | 259K | 351K | 157 K | 239K | 200K | Copyright ©2026 Penumbra, Inc. All rights reserved. 6 Copyr ...

Core Insights - The article compares Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN) to determine which stock offers better value for investors [1] Valuation Metrics - CLPBY has a forward P/E ratio of 21.75, significantly lower than PEN's forward P/E of 63.30 [5] - CLPBY's PEG ratio is 0.84, indicating a more favorable earnings growth outlook compared to PEN's PEG ratio of 1.97 [5] - CLPBY's P/B ratio stands at 8.32, while PEN's P/B ratio is higher at 9.29 [6] Zacks Rank - CLPBY currently holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, whereas PEN has a Zacks Rank of 3 (Hold) [3] Value Grades - Based on various valuation metrics, CLPBY has a Value grade of B, while PEN has a Value grade of D, suggesting that CLPBY is the superior value option at this time [6]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

Group 1 - Major indexes experienced a mixed week, with Allient (ALNT) and Wabtec (WAB) reaching new highs, alongside health technology company Penumbra (PEN) trading in or near buy zones [5] - Allient stock has shown a significant turnaround in growth and demand, outperforming all Mag 7 stocks year to date [6] - Wabtec stock has reached a record high, driven by strong profit growth, indicating a bullish signal for the industrial tech sector [8] Group 2 - Oracle's stock jumped following reports that TikTok signed a deal to create a U.S. joint venture, highlighting the impact of strategic partnerships on stock performance [7] - Penumbra is noted for showing improved relative strength, indicating potential for further growth in the health technology sector [10] - Caterpillar is in a buy zone after a recent breakout move, suggesting positive momentum in the Dow Jones stocks [10]

Sometimes you get busy, forget to come back around on a name, and miss an opportunity. Such is the case for me with Penumbra ( PEN ). I’ve liked this player in mechanical thrombectomy forAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...